Expression of insulin-like growth factor I (IGF-I) mRNA by some tumor cell lines of neuroectodermal origin has been described. To further explore the significance of IGF-I mRNA expression in these tumors, a more extensive analysis was performed. Most (9 of 10) neuroectodermal tumor cell lines with a t(11;22) translocation (primitive neuroectodermal tumor IPNETI, Ewing's sarcoma, esthesioneuroblastoma) expressed IGF-I mRNA, whereas 0 of 15 cell lines without the translocation (PNET, neuroblastoma) expressed IGF-I. Furthermore, inasmuch as all neuroblastoma (12 of 12) cell lines examined expressed IGF-II RNA, the pattern of IGF expression could distinguish between these closely related tumors. CHP-100, a PNET cell line with the t(11;22) translocation, was shown to secrete both IGF-I protein and an IGF binding protein, IGFBP-2. This cell line also expressed the type I IGF receptor mRNA, and blockade of this receptor by a monoclonal antibody (aIR3) inhibited serum-free growth. These data demonstrate that IGF-I expression is a property of neuroectodermal tumors with a t(l 1;22) translocation and that interruption of an IGF-I autocrine loop inhibits the growth of these tumor cells.
Introduction
The autocrine growth hypothesis states that malignant cells can produce and secrete polypeptide growth factors that will bind to their own cell surface receptors and stimulate proliferation (1) . In order to prove that a secreted growth factor acts via an autocrine pathway, there must be demonstration that the ligand and its receptor are expressed by the cell, that interference with the ligand-receptor interaction inhibits tumor cell growth, and that the growth inhibition caused by this interference is specific. Although growth factors have been reported to function as autocrine growth stimulators in several types of solid tumors (2) (3) (4) (5) , direct demonstration of these points, espe-Insulin-like growth factor I (IGF-I)' is a growth factor important in normal growth and development and is expressed by many normal cells of mesenchymal origin (6) . IGF-I has been reported to be an autocrine growth factor for a variety of tumors (7-1 1); however, using a ribonuclease (RNase) protection assay, we have found that authentic IGF-I mRNA is rarely expressed in tumor cell lines of epithelial origin (12) . Previous reports of IGF-I expression may be spurious, owing to the nonspecific detection of cross-reacting mRNAs by the IGF-I cDNA and/or to interference with the IGF-I radioimmunoassay (RIA) by IGF binding proteins.
Neuroblastoma and primitive neuroectodermal tumors (PNETs, also known as peripheral neuroepithelioma) are extracranial tumors that originate from primitive neuroectoderm (13) . Although these small round cell tumors can be histologically confused, they may be distinguished from one another by biochemical markers, cell surface antigens, ultrastructural features, patterns of oncogene expression, and presence or absence of a t( 11 ;22)q( 12:24) chromosomal translocation (13) (14) (15) (16) (17) (18) (19) (20) . For example, neuroblastomas express enzymes for catecholamine synthesis and often have amplification of the N-myc oncogene. In contrast, PNETs do not express adrenergic enzymes, have low levels of N-myc expression, do not have N-myc genomic amplification, express choline acetyl transferase, and often have a characteristic t(1 1;22) chromosomal translocation. This translocation can be seen in other tumors, including Ewing's sarcoma, suggesting that this tumor also arises from a neuroectodermal progenitor (13) (14) (15) . We have previously reported that some neuroectodermal tumor cell lines bearing this chromosomal translocation expressed IGF-I mRNA (12) . In (SK-PN-LI, SK-PN-DW,  SK-N-RA, SK-M-AS, SK-N-FI) .
Cell lines. The cell lines were maintained in RPMI 1640 and 10% heat-inactivated fetal calf serum in a humidified atmosphere containing 5% CO2. Cell lines established from neuroectodermal tumors containing the t( 11 ;22) translocation are PNETs (CHP-100, SK-N-MC, TC-135, and TC-32), esthesioneuroblastoma (JFEN), and Ewing's sarcomas (TC-106, 5838, A4573, A9423, 6647) (13) (14) (15) (16) (21) (22) (23) . CB-AGPN, SK-PN-DW, and SK-PN-LI are PNET cell lines without the t( 11 ;22) chromosomal translocation (18, 24) (J. Whang Peng, personal communication). SK-N-RA, SK-N-SH, SMS-LHN, LA-N-6, SK-N-AS, and SK-N-FI are neuroblastoma cell lines that lack N-myc genomic amplification (18, 23, 25) . SMS-KAN, SMS-KCN, SMS-KCNR, SMS-SAN, SMS-MSN, and SK-N-BE(1) are N-myc amplified neuroblastoma cell lines (18, 26, 27) .
RNase protection assays. RNase protection assays were performed as previously described (28 (32) . Bovine serum binding proteins were isolated by a previously described method (33) and -250 ng of each binding protein was applied to the same gel as the CHP-100 conditioned media.
Western immunoblotting was performed using an antiserum directed against MDBK-BP, the IGF binding protein produced by MDBK (normal bovine kidney) cells (34) . 500 ng of MDBK-BP, human IGFBP-l (hBP-25), each serum bovine binding protein, and 40
Ml of 2,500-fold concentrated CHP-l00-conditioned medium were fractionated on a 12% SDS-PAGE gel under nonreducing conditions. The proteins were transferred to nitrocellulose and incubated with a 1:500 dilution of the MDBK antiserum and developed as previously described (35 Table I ). Similar studies using an IGF-II cDNA in RNase protection assay showed that all neuroblastoma cell lines (12 of 12) examined expressed IGF-II mRNA ( Fig. 1 C and Table I ). Both N-myc amplified and nonamplified cell lines expressed IGF-II mRNA. None of the IGF-I expressing neuroectodermal tumor cell lines known to have the t(11 ;22) chromosomal translocation expressed IGF-II mRNA. Therefore, the pattern of IGF expression distinguished between closely related neuroectodermal tumors.
All cell lines examined expressed type I IGF receptor mRNA (Fig. 2, A (Fig. 3) . The larger peak centered close to 50 kD was compatible with the molecular mass of some IGF binding proteins.
The smaller peak at -14-10 kD was compatible with the size and elution position for authentic IGF-I. Using an identical gel filtration column, we previously demonstrated that the elution position ofauthentic radiolabeled IGF-I was found in a similar range of column fractions (30) . In addition, we examined the fractions for IGF-I binding protein using the charcoal separation assay and found that after acid treatment, only the larger molecular mass fractions contained IGF binding activity (Fig. 3) . The smaller peak had no binding protein activity detectable by charcoal separation assay. Therefore, the smaller peak represents authentic immunoreactive IGF-I protein produced by CHP-100.
In order to identify the species of IGF binding protein contained in the larger peak, we performed Western ligand blots on concentrated CHP-100 conditioned media (Fig. 4) . (37, 39 ).
To further demonstrate that CHP-100 expressed IGFBP-2 we used an antisera directed against the MDBK (normal bovine kidney cells) IGF binding protein (bovine IGFBP-2) (34) in Western immunoblot. Fig. 4 demonstrates that this antisera detected 34-kD purified bovine IGFBP-2 (lane 4), and a 34-kD band in bovine serum (lane 7) and CHP-100-conditioned media (lane 6). Therefore, the IGF binding protein is immunologically related to bovine IGFBP-2. Since the MDBK and human IGF (IGFBP-2) binding proteins are homologous (34, 38) , these observations suggest that the 34-kD binding protein produced by CHP-100 is human IGFBP-2. Therefore, the larger IGF-I immunoreactive peak detected on RIA of the gel-filtered CHP-100-conditioned media was most likely produced by artifactual interference of IGFBP-2 with the IGF-I RIA.
Growth effects of type I IGF receptor blockade. Since CHP-I00 expressed IGF-I, IGFBP-2, and type I IGF receptor mRNA, we examined the possibility that IGF-I could serve as an autocrine growth factor for this tumor by studying the effects of antibody blockade of the receptor. We grew the cells in the presence of 26 ,ug/ml of an antibody (aIR3) directed against the type I IGF receptor (40) . aIR3 has been shown to block the binding of IGF-I to the type I IGF receptor at a concentration of 13 jig/ml without eliciting a biological response (36, 41) . Under serum-free conditions, this concentration of antibody inhibited the growth stimulatory effects of exogenous IGF-I on CHP-100, but was ineffective at decreasing basal growth (data not shown). However, higher concentrations of aIR3 decreased cell number by 25 cific isotypic IgG (26 ug/ml) had no effect on the growth of the cells (Figs. 5 A and 6) . Exposure of the cells to exogenously added IGF-I (10-100 nM) after aIR3 treatment reversed the growth inhibition of aIR3 (Fig. 6) and cells grew at control levels. Although the highest concentration of IGF-I resulted in growth stimulation, this result did not achieve statistical significance (Fig. 6, expt. 4 ). Additionally, aIR3 had no effect on the growth of SK-PN-DW, a PNET cell line which expressed type I IGF receptor mRNA but neither IGF-I or IGF-II mRNA (Figs. 1 A, 2, and 5 B) . The results of five individual experiments are demonstrated in Fig. 6 . aIR3 caused statistically significant growth inhibition of CHP-100 cells when compared to their basal growth in serum-free media. Since excess ligand could reverse this effect and no growth inhibition was demonstrated in a non-IGF producing cell, this suggests that interruption of the IGF-I ligand-receptor interaction by aIR3 blockade of the receptor caused specific growth inhibition of CHP-100.
Discussion
In the human central nervous system the expression of both IGF-I and -II is low (23, 42, 43) although little is known about the pattern of IGF expression in the peripheral nervous system. However, in proliferating embryonic neurons isolated from rodent brain, IGF-I mRNA expression has been reported (44). Based on this observation, it has been suggested that IGF-I may be an autocrine growth factor for proliferating neuroblasts. IGF-I has been shown to be an autocrine growth factor for normal rodent glial cells (45). In other epithelial cells, studies in nontransformed breast cancer cells and colon cells line have demonstrated that an analogous autocrine pathway, composed of a TGFa/EGF receptor loop, is operative (46, 47) . These data support the concept that autocrine pathways are not only a feature of malignant epithelial cells, but may also be found in normal or premalignant proliferating cells. A lack of regulation or an alteration in the response to these pathways may be important in the unregulated cellular proliferation that characterizes cancer. It is possible that unregulated IGF-I expression by tumors derived from neural pre- . It seems likely that expression of IGF binding proteins along with expression of IGF-I could be important in the autocrine growth regulation of the tumor. Of note is that IGFBP-2 contains an Arg-Gly-Asp (RGD) sequence which may be important in cell surface binding (38) and could influence the interaction between IGF-I and its receptor. Further study of the functions of the IGF binding proteins should clarify their roles in modulating IGF action.
We have shown that blockade of the type I IGF receptor with the monoclonal antibody aIR3 inhibited CHP-100 proliferation. However, because aIR3 alone causes serine phosphorylation of the type I IGF receptor (51) , this antibody may induce some incompletely characterized physiological effects. aIR3 has been reported to have antiproliferative effects in small-cell lung cancer (7), pancreatic cancer (11), and neuroblastoma (5), but it is unclear if these results are specifically due to the interruption of an IGF-mediated autocrine loop. We have found that aIR3 did not inhibit the growth of a PNET (SK-PN-DW) cell that expressed the type I IGF receptor but did not express IGF-I or IGF-II, that nonspecific IgG did not inhibit CHP-100 growth, and that the effects of aIR3 on CHP-100 could be partially reversed by excess IGF-I. These observations support the concept that the antiproliferative effects of aIR3 on CHP-100 cells were specific and due to its ability to block the IGF-I ligand-receptor interaction, and suggest that IGF-I is an autocrine growth factor for these PNET cells.
Interruption of the IGF-I autocrine loop required higher concentrations of aIR3 than those needed to block the effects of exogenously added IGF-I. In addition, the inhibition caused by antibody is only partial and excess IGF-I added in the presence of aIR3 could not stimulate growth above control levels. Several factors may account for these observations. The production of IGF binding proteins may alter the receptor's affinity for IGF-I. If IGF binding proteins enhance the ability of the type I IGF receptor to bind IGF-I, then it may be more difficult to interrupt this ligand-receptor interaction by aIR3. It is possible that IGF-I may bind and activate its receptor intracellularly as has been described for platelet-derived growth factor (52) . This would lead to activation of the type I IGF receptor that could not be interrupted by an antibody delivered to the extracellular space. In addition, IGF-I may be bound to its receptor as the receptor is transported to the cell surface. In either of these conditions, it could be postulated that higher concentrations of antibody would be needed to interrupt this "pre-bound" ligand-receptor interaction than would be needed to block exogenous ligand. These possibilities are being examined.
Using Northern blot analysis, El-Badry et al. (5) demonstrated that neuroblastoma cells expressed IGF-II mRNA. We have used RNase protection assay, a more sensitive and specific method of detecting IGF mRNA transcripts (12, 53) , and have confirmed that 12 of the neuroblastoma cell lines we studied express IGF-II. Since the panel of neuroblastoma cell lines we studied included both N-myc gene amplified and nonamplified cells, these data suggest that IGF-II expression is common to all neuroblastoma cell lines. Since we have shown that IGF-I mRNA is expressed by 9 of 10 neuroectodermal tumor cell lines bearing the t(l 1;22) chromosomal translocation and that neither IGF-I or IGF-II is expressed by PNET cell lines that lack the t(I 1;22) translocation, the pattern of IGF expression can distinguish between cell lines derived from closely related neuroectodermal tumors.
The IGF-I gene is located on chromosome 12 and little is known about the molecular mechanisms that account for the regulation of its expression. Of note is the association of the chromosomal translocation and expression of IGF-I mRNA. It is not known if the translocation acts directly to initiate IGF-I expression or whether IGF-I expression is a property ofa cell lineage that frequently develops the translocation during oncogenesis. If the translocation is involved in the activation of the IGF-I gene, this would suggest a mechanism by which this genetic event could be responsible for the autocrine growth stimulation of PNET, and potentially Ewing's sarcoma, by IGF-I. Similarly, the observation that IGF-II is produced by all neuroblastoma cell lines that we examined, suggest that autocrine stimulation of these tumors by IGF-II may be a common event.
Interference with the interaction of IGF-I or IGF-II with the type I IGF receptor in tumors of neuroectodermal origin has now been demonstrated to slow in vitro tumor growth (5). aIR3 mediated type I IGF receptor blockade has also been shown to slow breast cancer cell growth in an in vivo athymic mouse model (54) . Taken together, these studies suggest that interference of the IGF receptor-ligand interaction may prove to be an important therapeutic modality for many types of tumors.
